Celldex's Barzolvolimab Shows Rapid, Durable Responses In Early Urticaria Study

  • Celldex Therapeutics Inc CLDX announced interim data from Phase 1b trial of barzolvolimab in chronic spontaneous urticaria (CSU) refractory to antihistamines. 
  • CSU is characterized by the occurrence of hives or weals for six weeks or longer without identifiable specific triggers or causes.
  • Data show that multiple doses of barzolvolimab resulted in dose-dependent decreases in itch and hives, with a mean UAS7 reduction of 66.6% in the 1.5 mg/kg dose group (n=8) at week 12 and 75.1% in 3.0 mg/kg dose group (n=9) at week 8, demonstrating meaningful symptom improvements for patients. 
  • Complete response was 57.1% for the 1.5 mg/kg dose group and 44.4% for 3.0 mg/kg dose group.
  • Barzolvolimab demonstrated a favorable safety profile, supporting Phase 2 clinical development.
  • The Phase 1b study is expected to enroll approximately 40 patients with CSU across four cohorts, either alone or in combination with H2-antihistamines and/or leukotriene receptor agonists. 
  • Price Action: CLDX shares are down 14.95% at $22.93 during the market session on the last check Friday.

Posted In: BriefsBiotechNewsHealth CareSmall CapMoversTrading IdeasGeneral

Ad Disclosure: The rate information is obtained by Bankrate from the listed institutions. Bankrate cannot guaranty the accuracy or availability of any rates shown above. Institutions may have different rates on their own websites than those posted on Bankrate.com. The listings that appear on this page are from companies from which this website receives compensation, which may impact how, where, and in what order products appear. This table does not include all companies or all available products.

All rates are subject to change without notice and may vary depending on location. These quotes are from banks, thrifts, and credit unions, some of whom have paid for a link to their own Web site where you can find additional information. Those with a paid link are our Advertisers. Those without a paid link are listings we obtain to improve the consumer shopping experience and are not Advertisers. To receive the Bankrate.com rate from an Advertiser, please identify yourself as a Bankrate customer. Bank and thrift deposits are insured by the Federal Deposit Insurance Corp. Credit union deposits are insured by the National Credit Union Administration.

Consumer Satisfaction: Bankrate attempts to verify the accuracy and availability of its Advertisers' terms through its quality assurance process and requires Advertisers to agree to our Terms and Conditions and to adhere to our Quality Control Program. If you believe that you have received an inaccurate quote or are otherwise not satisfied with the services provided to you by the institution you choose, please click here.

Rate collection and criteria: Click here for more information on rate collection and criteria.